New Drug-Related Prior Authorization (PA) for Xolair

Effective September 1, 2017, Blue Cross and Blue Shield of Minnesota and Blue Plus (Blue Cross) will require PA for Xolair (omalizumab). The intent of the Xolair (omalizumab) PA Criteria is to appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies while adhering to the dosing guidelines for age, weight, and pretreatment IgE levels (for allergic asthma) as recommended in FDA labeling. Xolair will not be allowed to be used in combination with an injectable IL-5 inhibitor indicated for asthma.

As stewards of healthcare expenditures for our subscribers, we are charged with ensuring the highest quality, evidence based care. One method for doing so is through the PA process. The primary purpose of the PA process is to ensure that evidence based care is provided to our subscribers, driving quality, safety, and affordability.

<table>
<thead>
<tr>
<th>Pharmacy Prior Authorization Program</th>
<th>Drug Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xolair (omalizumab) PA</td>
<td>Xolair (omalizumab)</td>
</tr>
</tbody>
</table>

Products impacted
This PA program applies to commercial lines of business and the following Minnesota Health Care Programs:
- Blue Advantage Prepaid Medical Assistance Program (PMAP)
- Minnesota Senior Care Plus (MSC+)
- MinnesotaCare

New PA criteria will be posted by August 1, 2017, and can be accessed using the Blue Cross provider link.
- Access providers.bluecrossmn.com
- Under Tools and Resources, select Medical policy, then acknowledge the Acceptance statement
- Select Utilization Management
- Select Pharmacy Utilization Management Programs

CoverMyMeds prior authorization request service
As a reminder, CoverMyMeds (CMM) is a free service to providers which allows quick and easy submission of PA requests. Experience with CMM by other plans has demonstrated marked reductions in physician office call-backs regarding PA requests, after CMM is implemented. PA requests may also continue to be faxed to their review destination external to the CMM portal, as is the current practice.

You may access CMM at www.covermymeds.com. Select Help (top right of the web page) to view FAQs and Support tutorials (3-5 minutes), including live online chat support to help you get started. You will need to open a CMM account to submit requests using the portal.

Questions?
If you have questions, please contact provider services at (651) 662-5200 or 1-800-262-0820.